Background: The safety and efficacy of doravirine were compared with that of efavirenz as initial treatment of adults living with HIV-1 infection.
Background: Most totally blind people have non-24-hour sleep–wake disorder (non-24), a rare circadian rhythm disorder caused by an inability of light to reset their circadian pacemaker.
Treatment options for adults with attention deficit hyperactivity disorder (ADHD) are limited. The study was conducted to confirm the clinically effective and safe dose of methylphenidate hydrochloride...
Protagonist Therapeutics, Inc. announced it has randomized 241 patients in the ongoing Phase III VERIFY clinical trial evaluating rusfertide in polycythemia vera ("PV") as and expects to meet the trial's 250 patient enrollment target by the end of March 2024
Boehringer Ingelheim has announced new data that show increase in FEV1 AUC0–12, a measure of lung function, with Stiolto Respimat...
Objective: To explore the clinical efficacy and safety of subcutaneous (SC) rozanolixizumab, an anti-neonatal Fc receptor humanized monoclonal antibody, in patients with generalized myasthenia gravis (gMG).
Objective: To evaluate the clinical effects of zilucoplan, a subcutaneously (SC) self-administered macrocyclic peptide inhibitor of complement component 5, in a broad population of patients with moderate to severe gMG.
Objective: To evaluate the efficacy and safety of brodalumab through 120 weeks of treatment in the AMAGINE-2 trial.
Background: First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for...